The two new board members bring decades of experience and expertise in drug development, manufacturing, clinical development and licensing from both biotech and big pharma perspectives. Joining the board are Christina Glad and Fredrik Juserius.
“We are excited to welcome Cristina and Fredrik to our board of directors. They bring decades of leadership in areas that will be vital to our future operations and strategy. Cristina has for example long experience in bringing drug targets from early stage to clinical development and has profound knowledge on the manufacturing of biologicals. Cristina has made the journey of starting a small biotech and developing it into a successful large company. Fredrik brings more than 25 years of experience as director within the pharmaceutical industry with particular expertise in vaccines, business strategy, licensing, negotiations and M&As. We are happy to have them both joining our board of directors” says Anders Ericson, Chairman of the Board of Abera.
“I am excited to join the board of directors at Abera Bioscience. The company has an exciting and promising technology with its universal pneumococcal vaccine representing a clear first indication that targets a clear need on the market. I look forward to contributing to the future development of Abera Bioscience”, says Fredrik Juserius.
“The dedicated team of Abera Bioscience has developed an interesting technology with great potential in numerous areas. I am looking forward to supporting the team with my knowledge and experiences when they now accelerate the pace and entering new stages of the development”, says Cristina Glad.
Cristina Glad holds a PhD in biochemistry and an Executive MBA. She has more than 25 years of experience within the biotech industry, in particular in the development of pharmaceuticals, development of production processes for antibody-based pharmaceuticals, setup of contract manufacturing operations, R&D cooperation with biotech and pharmaceutical companies, and in- and out-licensing of projects. In her previous role as CEO and vice-president, Cristina Glad was instrumental for the evolvement of BioInvent International AB from a technology platform company to a clinical-stage company with several drug candidates in its portfolio. Cristina Glad is an experienced board member and her current assignments include Chairman of the board at Guard Therapeutics and board member at RhoVac AB, Aptahem AB and Region Skåne Holdings AB. She is also a member of the Royal Swedish Academy of Engineering Sciences (IVA).
Fredrik Juserius holds as MSc in Industrial Engineering and Management and brings over 20 years of experience from leadership roles within the pharmaceutical industry. He currently holds a role as Nordic Business Operations Lead at Takeda and has previously held positions as Country Manager, North Europe Cluster Manager and Business strategy director at companies such as GSK, Allergan, Novartis and Shire. Fredrik Juserius has extensive experience with running effective business operations within both vaccine and oncology business and has particular expertise on in- and out licensing, M&A and large deal negotiations.
Alf Lindberg has decided to resign from the board, due to health reasons.